The National Institute of Oncology in Gliwice has launched a pioneering clinical study using a novel radiotracer for immuno-PET imaging. As one of the first initiatives of its kind in the region, the project marks a meaningful step forward for advanced diagnostics in Central and Eastern Europe.
At Axcellant, we closely follow developments in the field of nuclear medicine and molecular imaging, particularly where they intersect with clinical research. Imaging-based trials, such as this one, are not only scientifically ambitious but also logistically complex. Successfully executing such studies requires a deep understanding of regulatory frameworks, robust imaging infrastructure, and tight coordination between interdisciplinary teams.
Poland’s growing activity in this space is an encouraging sign for sponsors looking for experienced research partners beyond traditional Western hubs. As a CRO with strong expertise in imaging-supported clinical trials, we welcome this progress and look forward to supporting more innovation in the region.
Read the full article (in Polish) here.
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…
Copyright @ 2026 Axcellant